HALOG-E Drug Patent Profile

Which patents cover Halog-e, and when can generic versions of Halog-e launch?

Halog-e is a drug marketed by Sun Pharm Inds Inc and is included in one NDA.

The generic ingredient in HALOG-E is halcinonide. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the halcinonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Halog-e

A generic version of HALOG-E was approved as halcinonide by MYLAN on August 12^th, 2019.

Summary for HALOG-E

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	68
Patent Applications:	7,107
DailyMed Link:	HALOG-E at DailyMed

US Patents and Regulatory Information for HALOG-E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	HALOG-E	halcinonide	CREAM;TOPICAL	018234-001	Approved Prior to Jan 1, 1982		DISCN	No	No

HALOG-E Market Dynamics and Financial Trajectory: Fluocinonide Generic Competition, FDA Status, and Commercial Outlook

Last updated: August 1, 2026

HALOG-E is an older topical fluocinonide product used for corticosteroid-responsive dermatoses. Its commercial position has largely been displaced by generic fluocinonide products and newer topical corticosteroids. HALOG-E does not have a separately reported public revenue stream, and its current commercial value is materially lower than the value of the broader fluocinonide market.

The financial profile is therefore a mature, low-growth prescription topical market characterized by generic substitution, limited differentiation, low entry barriers for standard formulations, and weak brand pricing power.

What drug is HALOG-E and what is its active ingredient?

HALOG-E contains fluocinonide, a high-potency topical corticosteroid. Fluocinonide is used for inflammatory and pruritic corticosteroid-responsive skin conditions, including eczema, dermatitis, psoriasis, and related disorders.

Attribute	HALOG-E profile
Brand	HALOG-E
Active ingredient	Fluocinonide
Therapeutic class	Topical corticosteroid
Typical strength associated with the product	0.05%
Dosage forms historically associated with fluocinonide brands	Cream, ointment, gel, solution
Administration	Topical
Regulatory pathway	Prescription drug
Current commercial position	Mature or discontinued brand with generic substitution
Primary competitors	Generic fluocinonide and other high-potency topical corticosteroids

The "E" designation historically distinguished the product from other fluocinonide presentations, particularly formulations containing an emollient or vehicle intended to improve topical application. The commercial distinction between branded and generic versions has narrowed as physicians, pharmacies, and payers have favored lower-cost alternatives.

What is the FDA and Orange Book status of HALOG-E?

HALOG-E is an older fluocinonide product associated with the U.S. prescription market. Its active ingredient is well established, but the branded product is not a major current commercial asset.

FDA records distinguish between a drug’s historical approval and its current marketing status. A product may remain listed in FDA databases while being identified as discontinued or no longer marketed. That status does not necessarily indicate withdrawal for safety or efficacy reasons.[1]

The Orange Book evaluates approved drug products and their therapeutic-equivalence status. For a mature topical corticosteroid such as fluocinonide, the commercial market is driven primarily by currently marketed generic products rather than the legacy brand name.[2]

FDA regulatory status and market implications

The regulatory implications are:

• Fluocinonide is an established active pharmaceutical ingredient with substantial clinical history.
• Generic fluocinonide products can compete through abbreviated new drug applications when they meet applicable FDA requirements.
• The market does not depend on a new clinical development program for the active ingredient.
• Legacy brand protection is unlikely to support premium pricing where equivalent generic products are available.
• Product-specific discontinuation does not eliminate the commercial opportunity for other fluocinonide manufacturers.

No current FDA exclusivity period is expected to protect a legacy HALOG-E product. Any historical new-drug exclusivity would have expired decades ago.

When did HALOG-E lose exclusivity?

HALOG-E lost practical market exclusivity long before the current generic-drug era. The product belongs to an older generation of topical corticosteroid brands whose value was based on formulation recognition and physician familiarity rather than durable patent protection.

Relevant exclusivity categories are summarized below:

Exclusivity type	HALOG-E assessment
New chemical entity exclusivity	Expired
Five-year Hatch-Waxman exclusivity	Not commercially relevant to this legacy product
Three-year clinical-investigation exclusivity	Expired
Pediatric exclusivity	None currently relevant
Orphan-drug exclusivity	Not applicable
Current brand exclusivity	None of material commercial significance
Patent-based generic barrier	No material current barrier publicly associated with the legacy brand

The practical loss of exclusivity occurred through a combination of patent expiry, generic approvals, therapeutic substitution, and the availability of alternative topical corticosteroids.

What patents protect HALOG-E?

The historical HALOG-E product may have been associated with formulation and manufacturing rights, but no commercially meaningful, currently enforceable patent estate is generally associated with the legacy brand.

A patent review should separate three categories:

1. Active-ingredient patents. These cover fluocinonide itself or its chemical synthesis. Any such protection is historical and expired.
2. Formulation patents. These may cover vehicles, emulsion systems, gels, ointments, particle sizes, penetration enhancers, or stabilizers.
3. Method-of-use patents. These could cover treatment of specific dermatological conditions, but older topical corticosteroid indications generally have limited practical blocking power.

For a generic manufacturer, the key intellectual-property questions are not usually whether fluocinonide itself remains protected. They are whether a particular formulation, delivery vehicle, manufacturing process, or labeled indication is covered by an unexpired patent.

Are formulation patents a meaningful barrier?

Formulation patents can matter for differentiated topical products, but they are unlikely to preserve broad exclusivity for conventional HALOG-E-type cream or ointment products.

A formulation patent can have value when it produces:

• improved skin penetration;
• reduced irritation;
• better cosmetic acceptability;
• extended stability;
• a non-greasy or low-residue vehicle;
• a spray, foam, lotion, or other differentiated delivery system.

Those rights would protect the specific formulation rather than the entire fluocinonide market. Standard fluocinonide cream, ointment, gel, or solution products can generally compete if they avoid valid claims covering a proprietary vehicle or manufacturing process.

How many patents cover HALOG-E and fluocinonide?

There is no commercially relevant single patent count for HALOG-E. The answer depends on the jurisdiction, dosage form, formulation, patent family, and whether expired patents are included.

For market analysis, the estate is best characterized as follows:

Patent category	Current competitive significance
Fluocinonide compound patents	Expired or commercially obsolete
Historical HALOG-E formulation patents	Generally expired or no longer material
Conventional cream and ointment claims	Low barrier to generic competition
Novel delivery-system claims	Potentially relevant for newer products
Manufacturing-process claims	Relevant only if technically difficult to design around
Method-of-use claims	Narrow and generally weak against broad generic substitution

The relevant patent-risk question is therefore product-specific. A new foam, spray, lotion, or enhanced-penetration formulation may have a stronger patent position than a conventional HALOG-E cream equivalent.

Are there Paragraph IV challenges to HALOG-E?

Paragraph IV litigation is not a major current feature of the HALOG-E market. Paragraph IV certifications are most important when a generic applicant challenges an unexpired patent listed in the Orange Book for a branded reference product.

For an older topical corticosteroid brand with no material current patent exclusivity, generic entry typically occurs without a commercially significant patent dispute. The competitive process is more likely to involve:

• abbreviated new drug application approvals;
• therapeutic-equivalence determinations;
• pharmacy substitution;
• payer formulary placement;
• pricing negotiations.

A Paragraph IV challenge could arise for a later, reformulated fluocinonide product with Orange Book-listed patents. That would be a dispute involving the newer formulation, not necessarily the legacy HALOG-E product.

What is the competitive landscape for HALOG-E?

HALOG-E competes in two markets: the fluocinonide generic market and the broader high-potency topical corticosteroid market.

Generic fluocinonide competitors

Generic competitors may market fluocinonide in several dosage forms, including:

• cream;
• ointment;
• gel;
• solution;
• lotion or other topical vehicles, depending on approved product availability.

Generic pricing is shaped by the number of approved manufacturers, pharmacy-benefit-manager contracting, wholesaler inventory, product shortages, and dosage-form substitution.

Therapeutic competitors

Physicians can select other topical corticosteroids based on potency, body site, disease severity, vehicle, patient age, and reimbursement. Competitive products may include:

• clobetasol propionate;
• betamethasone dipropionate;
• desoximetasone;
• mometasone furoate;
• triamcinolone acetonide;
• hydrocortisone formulations for lower-potency use.

The market is segmented by potency and formulation. A low-cost generic fluocinonide product competes most directly with other high-potency topical corticosteroids rather than with every dermatology product.

What is the financial trajectory of HALOG-E?

HALOG-E has no separately disclosed public revenue trajectory comparable to a currently marketed major pharmaceutical brand. Its financial profile is best described as a decline from legacy brand sales to minimal or unreported commercial activity.

Period	Financial position
Original brand period	Revenue generated through branded prescription sales
Initial generic-entry period	Volume shifted toward lower-priced equivalents
Mature generic period	Brand price and share compressed
Current market	No material separately reported HALOG-E revenue
Forward outlook	Limited brand growth; value resides in generic fluocinonide supply

The absence of standalone revenue reporting is important. Public pharmaceutical companies generally report products at a portfolio or therapeutic-area level when sales are small. HALOG-E is therefore unlikely to represent a separately material revenue line for a current manufacturer.

Revenue exposure

The economic exposure lies in the broader class rather than the legacy brand:

• manufacturers of generic fluocinonide;
• suppliers of topical corticosteroid vehicles;
• contract manufacturers;
• distributors and wholesalers;
• companies developing differentiated dermatology delivery systems.

A generic fluocinonide product can generate stable unit demand but usually faces rapid price erosion once multiple suppliers enter. Profitability depends on manufacturing efficiency, supply reliability, channel contracts, and the ability to avoid excessive customer concentration.

What generic launch scenarios exist for HALOG-E?

Three commercial scenarios are relevant.

Scenario 1: Continued generic substitution

This is the base case. Pharmacies and payers continue to favor generic fluocinonide. HALOG-E remains commercially marginal or unavailable, while generic products retain volume with compressed prices.

Scenario 2: Short-term supply disruption

A manufacturing issue, product discontinuation, or shortage could temporarily increase demand for alternative fluocinonide suppliers. Such events may improve realized pricing, but the effect would likely be temporary because the active ingredient is mature and substitute topical corticosteroids are available.

Scenario 3: Reformulated product revival

A manufacturer could commercialize a differentiated fluocinonide product using a novel vehicle, delivery system, or patient-convenience feature. That product could command higher pricing if supported by clinical, regulatory, and patent differentiation. It would compete as a new formulation rather than as a simple revival of HALOG-E.

How strong is the HALOG-E patent estate?

The HALOG-E patent estate is weak from a current commercial perspective. The product has four structural disadvantages:

1. The active ingredient is old and widely available.
2. Generic substitution is established.
3. Historical exclusivity has expired.
4. Conventional topical formulations are difficult to defend through brand recognition alone.

Patent strength would be higher for a new formulation with narrow, technically meaningful claims. The strongest potential claims would relate to a specific vehicle, delivery system, manufacturing method, or clinically demonstrated performance advantage.

What licensing deals and litigation affect HALOG-E?

No major current licensing transaction or high-value litigation is generally associated with HALOG-E as a standalone commercial asset. The product’s age and generic competition reduce the incentive for material brand-specific licensing.

Potential transactions in the surrounding market would more likely involve:

• acquisition of generic topical portfolios;
• licensing of dermatology delivery technologies;
• contract manufacturing agreements;
• rights to differentiated foam, spray, lotion, or emulsion formulations;
• distribution arrangements for generic fluocinonide products.

Litigation risk is more likely to arise from product liability, manufacturing quality, regulatory compliance, or formulation patents covering newer products than from legacy HALOG-E brand rights.

How does HALOG-E compare with newer dermatology products?

Factor	HALOG-E	Newer differentiated topical product
Active ingredient	Mature fluocinonide	May use an established or new active
Brand differentiation	Low	Potentially high
Patent position	Weak or expired	May include formulation and delivery patents
Generic substitution	High	Depends on product-specific approvals
Pricing power	Low	Higher if clinically differentiated
Revenue visibility	Limited or none	Potentially measurable
Regulatory burden	Established product pathway	May require new formulation data
Manufacturing complexity	Generally moderate	Can be higher
Market growth	Low	Depends on disease area and delivery technology

Key Takeaways

• HALOG-E is a legacy fluocinonide topical corticosteroid brand with limited current standalone commercial significance.
• Its practical exclusivity expired long ago, and generic fluocinonide products now determine market pricing.
• No material current Orange Book exclusivity or patent barrier is associated with the legacy product.
• Paragraph IV litigation is not a central current risk for HALOG-E itself.
• Revenue data are not separately reported, indicating limited financial materiality as an individual brand.
• The broader fluocinonide market remains commercially viable but is exposed to generic price erosion.
• The strongest future value would come from differentiated formulations, delivery systems, manufacturing advantages, or branded dermatology portfolios rather than from the HALOG-E name.

FAQs About HALOG-E Market Value and Exclusivity

Is HALOG-E still available by prescription?

HALOG-E is generally treated as a legacy or discontinued brand rather than a major actively marketed prescription product. Fluocinonide remains available through generic products and other formulations.

Is fluocinonide still patent protected?

The fluocinonide active ingredient is not protected by meaningful current compound exclusivity. Specific newer formulations or delivery systems may have separate patents.

Can a generic manufacturer launch fluocinonide without a Paragraph IV lawsuit?

Yes. A generic applicant can enter without a Paragraph IV dispute when no relevant unexpired Orange Book patent blocks the reference product or when the applicant uses a non-infringing formulation.

What determines the profitability of generic fluocinonide?

The main factors are the number of suppliers, dosage form, manufacturing cost, pharmacy and payer contracts, supply reliability, and competitive price reductions.

Is HALOG-E a valuable licensing asset?

As a standalone legacy brand, HALOG-E has limited licensing value. Greater value may exist in a broader topical dermatology portfolio or in proprietary fluocinonide delivery technology.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
3. U.S. Food and Drug Administration. (n.d.). FDA label information for fluocinonide topical products. https://dailymed.nlm.nih.gov/dailymed/
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and generic drug information. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/ f